Chargement en cours...
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma
BACKGROUND AND PURPOSE: Isotretinoin (13-cis-retinoic acid; 13-cRA) is a differentiation inducer used to treat minimal residual disease after myeloablative therapy for high-risk neuroblastoma. However, more than 40% of children develop recurrent disease during or after 13-cRA treatment. The plasma c...
Enregistré dans:
| Publié dans: | Br J Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BlackWell Publishing Ltd
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4294043/ https://ncbi.nlm.nih.gov/pubmed/25039756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12846 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|